Reviews Supplements ECOGS September 2012 : Page 1
East Coast Optometric Glaucoma Symposium Highlights from the live event. 2012 Release Date: September 2012 Expiration Date : September 30, 2013 Goal Statement: Glaucoma affects more than 2.2 million Americans over the age of 40 and can lead to per-manent vision loss and blindness if not treated. This course will cover the steps taken in establishing the diagnosis of glaucoma, information from the glaucoma clinical trials, risk assessment for ocular hypertension, and the relevance of monocular trials and target pressures. Faculty/Editorial Board: Murray Fingeret, O.D., John Flanagan, M.C.Optom., Ph.D., David S. Friedman, M.D., Ph.D., Richard J. Madonna, M.A., O.D., Tony Realini, M.D., M.P.H. Credit Statement: This course is COPE approved for 2 hours of CE credit. COPE ID is 35171-GL. Please check your state licensing board to see if this approval counts toward your CE requirement for relicensure. Joint-Sponsorship Statement: This continuing education course is joint sponsored by the University of Alabama School of Optometry and Alcon Medical Education. Disclosure Statement: Dr. Fingeret is a consultant for Carl Zeiss Meditec, Alcon and Allergan. Dr. Flanagan is a consultant and speaker for Heidelberg Engineering and has received research funding from Heidelberg Engineering, Optovue Inc. and Photon etc. His spouse is a speaker for CIBA Vision. Dr. Friedman is a consultant for Pfizer, Alcon, Allergan, Merck and Bausch + Lomb. Dr. Madonna is a is on the advisory boards of Allergan, Carl Zeiss Meditec and Alcon and is a speaker for Alcon as well as Haag-Streit. Dr. Realini has no financial relationships to disclose. The science of glaucoma evaluation and management continues to evolve at a rapid pace. Concurrently, optimal clinical practice patterns change regularly as well. What is the right way to evaluate a glaucoma patient today? What tests should we use? What risk factors matter and how should risk guide treatment decisions? What are the newest treatment options and how do we select the best treatment for each individual patient? The East Coast Optometric Glaucoma Symposium was designed to answer these and other important questions facing the optometrist who manages glaucoma today. We have assembled a fantastic faculty of respected clinicians—both optometrists and ophthalmologists—to assist us in addressing the needs of today’s glaucoma patient. We hope the information they share improves your patients’ outcomes. Murray Fingeret, O.D. This course is sponsored by an educational grant from Alcon Medical Education.